Table 3.
Clinical, demographic and laboratory parameters of patients with isolated thrombotic APS, positive and negative for B2-CIC (N=196).
| ISOLATED THROMBOTIC APS (N=196) | ||||||
|---|---|---|---|---|---|---|
| CONDITION | B2-CIC positive N=73, 37.2% | B2-CIC negative N=123, 62.8% | p-value | OR/Hodges-Lehmann Median Difference (95% CI) | ||
| N/median | %/IQR | N/median | %/IQR | |||
| Age (years) | 54.0 | 41.0-61.3 | 50.0 | 40.3-58.0 | 0.205 | |
| Sex (women) | 46 | 63.0 | 67 | 54.5 | 0.243 | |
| Disease duration (years) | 5.0 | 3.0-10.0 | 5.0 | 2.0-10.0 | 0.393 | |
| Systemic lupus erythematosus | 30 | 41.1 | 51 | 41.5 | 0.960 | |
| Primary APS | 36 | 49.3 | 63 | 51.2 | 0.797 | |
| SAD-APS | 37 | 50.7 | 60 | 48.8 | 0.797 | |
| Catastrophic APS | 0 | 0.0 | 4 | 3.3 | 0.299 | |
| Arterial thrombosis | 32 | 43.8 | 63 | 51.2 | 0.319 | |
| Venous thrombosis | 43 | 58.9 | 65 | 52.8 | 0.170 | |
| Inf. extr. deep vein thrombosis | 31 | 42.5 | 50 | 40.7 | 0.455 | |
| Superficial thrombophlebitis | 15 | 20.5 | 18 | 14.6 | 0.286 | |
| Sup. extr. arterial thrombosis | 1 | 1.4 | 6 | 4.9 | 0.239 | |
| Acute myocardial infarction | 4 | 5.5 | 5 | 4.1 | 0.729 | |
| Stroke | 20 | 27.4 | 36 | 29.3 | 0.780 | |
| Pulmonary embolism | 7 | 9.6 | 13 | 10.6 | 0.827 | |
| Valve thickening and dysfunction | 4 | 5.5 | 1 | 0.8 | 0.047 | 7.07 (1.03-47.97) |
| Thrombocytopenia | 22 | 30.1 | 20 | 16.3 | 0.022 | 2.22 (1.11-4.44) |
| Hypocomplementemia | 24 | 32.9 | 28 | 22.8 | 0.141 | |
| C3 levels (mg/dL) | 109.0 | 90.0-130.0 | 135.5 | 108.5-161.5 | <0.001 | 27.0 (15.0-39.0) |
| C4 levels (mg/dL) | 18.8 | 13.0-25.8 | 26.2 | 17.2-35.5 | 0.001 | 7.10 (3.30-11.10) |
| Platelets (x103/μL) | 198.0 | 130.0-253.3 | 244.0 | 203.3-292.3 | 0.001 | 46.0 (21.0-76.0) |
| IgG aCL positive | 47 | 64.4 | 57 | 46.3 | 0.011 | 2.18 (1.19-3.97) |
| IgM aCL positive | 35 | 47.9 | 45 | 36.6 | 0.100 | |
| IgG B2GP1 positive | 43 | 58.9 | 56 | 45.5 | 0.071 | |
| IgM B2GP1 positive | 36 | 49.3 | 53 | 43.1 | 0.399 | |
| LA positive | 57 | 78.1 | 88 | 71.5 | 0.314 | |
| B2G-CIC positive | 26 | 35.6 | Na | Na | Na | |
| B2M-CIC positive | 58 | 79.5 | Na | Na | Na | |
| Triple aPL positivity | 43 | 58.9 | 49 | 39.8 | 0.010 | 2.17 (1.20-3.90) |
| Antiplatelet agents | 35 | 47.9 | 78 | 63.4 | 0.028 | 0.51 (0.28-0.93) |
| Anticoagulants | 64 | 87.7 | 106 | 86.2 | 0.817 | |
| Treated | 68 | 93.2 | 111 | 90.2 | 0.477 | |
aB2GP1, anti-β2-glicoproteína-I antibodies; aCL, anti-cardiolipin antibodies; LA, lupus anticoagulant; B2G-CIC, immune-complexes formed by B2GP1 and IgG aB2GP1 antibodies; B2M-CIC, immune-complexes formed by B2GP1 and IgM aB2GP1 antibodies. Significant p-values <0.05 are represented in bold.